Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 1 pseudogene 50 (HMGB1P50) is a predicted processed pseudogene related to the high mobility group box 1 (HMGB1) protein family. Pseudogenes, including those related to HMGB1, commonly result from gene duplication or retrotransposition events and do not typically encode functional proteins. Some pseudogenes are transcribed and may indirectly regulate their parental gene by acting as competitive endogenous RNAs (ceRNAs) or miRNA decoys, but there is no evidence that HMGB1P50 has such a role. HMGB1P50 is not considered a receptor, enzyme, transporter, or functional therapeutic target. There is no documented role for HMGB1P50 in disease, nor are there any drugs known to interact with it. The designation "HMGB1P50" is likely a database identifier used to mark its sequence relationship to HMGB1, rather than a name for a biologically active entity. If explicit functional, clinical, or therapeutic attributes of HMGB1P50 are required, further research or experimental evidence would be necessary. Currently, it is best categorized as a non-functional genomic pseudogene, and not a validated target for drug discovery or biomarker usage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 1 pseudogene 50 (HMGB1P50).